ClinicalTrials.gg

Program

prifetrastat

Also written as “PF-07248144”, “Prifetrastat” and “prifetrastat Test 1”.

In Pfizer's pipeline, KAT6 epigenetic modifier. Its studies are mostly in Renal Insufficiency · Carcinoma, Non-Small-Cell Lung · Breast Neoplasms, led by Pfizer.

Furthest: phase 3, since Jul 3, 202510 company-led studies, 5 open or runningNext primary completion: Dec 8, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer105 open or runningphase 3since Jul 3, 2025Oct 5, 2020Dec 8, 2026phase 1 · NCT07721402
  • Named in Pfizer’s own pipeline as prifetrastat PF-07248144, phase 3, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 5, 2020First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT04606446 · 320 planned · United States, Australia, China and more
  2. Jul 3, 2025Phase 3 study in Breast NeoplasmsNCT07062965 · 400 planned · United States, Argentina, Australia and more
  3. Jul 17, 2025Phase 1 study in Healthy AdultsNCT07636018 · 12 enrolled · Belgium
  4. Aug 5, 2025Phase 1 study in Healthy AdultsNCT07117799 · 24 enrolled · United States
  5. Sep 25, 2025Phase 1 study in Healthy AdultsNCT07198035 · 12 enrolled · Belgium
  6. Nov 20, 2025Phase 1 study in Healthy Adult ParticipantsNCT07423286 · 8 enrolled · United States
  7. Jan 5, 2026Phase 1 study in Healthy Adult ParticipantsNCT07335419 · 12 enrolled · United States
  8. Jul 16, 20262 phase 1 studiesNCT07721402, NCT07731100
  9. Nov 5, 2026Phase 1 study in Renal InsufficiencyNCT07933848 · 24 planned · United States

Ahead

  1. Dec 8, 2026Primary completion: phase 1 study in Healthy ParticipantNCT07721402
  2. Jul 22, 2027Primary completion: phase 3 study in Breast NeoplasmsNCT07062965
  3. May 21, 2028Primary completion: phase 1 study in Renal InsufficiencyNCT07933848
  4. Aug 27, 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT04606446

TargetBeta

“KAT6 epigenetic modifier”the company's pipeline, read by Claude · source
“An inhibitor of MYST histone acetyltransferase (HAT) KAT6, with potential antineoplastic activity. Upon administration, prifetrastat targets and binds to KAT6, and inhibits the acetylation of histones and other nonhistone substrates. This may disrupt gene expression and inhibit the proliferation …”NCIt, read by Claude

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
KAT6A/B Inhibitor BG-75202ruleBeOne Medicinesphase 12
HRS-2189Jiangsu HengRui Medicinephase 12
KAT6 Inhibitor OP-3136ruleolema-pharmaceuticals-incphase 11
KAT6/KAT7 Inhibitor PF-08032562rulePfizerphase 11
KAT6/KAT7 Inhibitor IDE574ruleideaya-biosciencesphase 11
HLX97Fosun Pharmaphase 11

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07933848Renal Insufficiency · United States1Not yet recruitingMay 21, 202824
NCT07731100Healthy Adults · United States1Not yet recruitingSep 10, 202612
NCT07721402Healthy Participant · Belgium1RecruitingDec 8, 202632
NCT07335419Healthy Adult Participants · United States1CompletedFeb 22, 202612
NCT07423286Healthy Adult Participants · United States1CompletedDec 28, 20258
NCT07198035Healthy Adults · Belgium1CompletedDec 17, 202512
NCT07117799Healthy Adults · United States1CompletedJun 18, 202524
NCT07636018Healthy Adults · Belgium1CompletedOct 8, 202512
NCT07062965Breast Neoplasms · United States, Argentina, Australia and more3RecruitingJul 22, 2027400
NCT04606446Carcinoma, Non-Small-Cell Lung · United States, Australia, China and more2RecruitingAug 27, 2029320

How it is read

Names in the registry

  • “PF-07248144”, 8 entries
  • “Prifetrastat”, 2 entries
  • “prifetrastat Test 1”, 1 entry
  • “prifetrastat Test 2”, 1 entry
  • “Oral [14C] PF-07248144”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.